LEMAITRE VASCULAR, INC. Debt Securities, Available-for-sale, Amortized Cost
LEMAITRE VASCULAR, INC. (LMAT) had Debt Securities, Available-for-sale, Amortized Cost of $350.59 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $350.59M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $341.24M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $273.24M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $350.59M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $341.24M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $273.24M 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NovoCure Ltd (NVCR) | $1.886B | -11.87 | |
| Inspire Medical Systems, Inc. (INSP) | United States | $1.990B | 9.55 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| UFP TECHNOLOGIES INC (UFPT) | United States | $2.308B | 28.37 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |